Our studies demonstrated that the levels of TNF-α and IL-1β in CFS of drug treatment groups were significant lower than that in control group on 24 weeks and 48 weeks. This evidence concerns the gene TNF and myalgic encephalomeyelitis/chronic fatigue syndrome.